A Roadmap for Estimated Glomerular Filtration Rate: Where Have We Been, Where Are We Now, and Where Do We Need to Go?
نویسندگان
چکیده
منابع مشابه
I-36: Preimplantation Genetic Diagnosis - Where Have We Been and Where Are We Going
Preimplantation genetic diagnosis (PGD) is now considered routine in IVF laboratories with micromanipulation capability and access to genetic diagnostic services. The past two decades have witnessed a dramatic increase in the use of PGD, the number of cycles performed, and the indications for which PGD has been used. This increase has been mirrored by a slow, but steady, increase in the range o...
متن کاملReflection for the undergraduate on writing in the portfolio: where are we now and where are we going?
Introduction: The portfolio can be seen as a tool for assessmentof a variety of learning activities that differ in content, usage, andassessment. The portfolio not only meets the learner’s educationalneeds but also the political and public reassurance demand thatthe health professional has achieved the required competency ofthe curriculum that allows him or her to practice safely with orwithout...
متن کاملEmployment for persons with disabilities: Where are we now and where do we need to go?
Nicki is a 21-year-old student with moderate intellectual disabilities who lives with her family. She has limited expressive language and communicates primarily through her body language and willingness to participate in activities. Nicki participated in a community-based vocational education program and then received supported employment services to assist her with gaining and maintaining a jo...
متن کاملExperimental therapeutics in prostate cancer: where are we now and where do we need to go.
T he explosion of new therapeutics in metastatic castrate-resistant prostate cancer (mCRPC) is unprecedented, but much more work needs to be done before we are satisfied. Six phase III trials with an overall survival impact have now been reported (Table 1). Four of these trials were exclusively or predominantly in the mCRPC post-docetaxel space (MDV3100, abiraterone, radium and cabazitaxel). Th...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Advances in Chronic Kidney Disease
سال: 2018
ISSN: 1548-5595
DOI: 10.1053/j.ackd.2017.10.009